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New-onsetdiabetesaftertransplantation(NODAT)iscommonafterlivertransplantandassociatedwithpooreroutcomes.Theaim
of this study was to identify risk factors for NODAT in liver transplant recipients oﬀ corticosteroids. In 225 adult nondiabetic liver
transplant recipients, the mean age was 51.7 years, the majority were men (71%), and half had HCV (49%). The mean calculated
MELD score at transplantation was 18.7, and 19% underwent living-donor transplant (LDLT). One year after transplantation,
17% developed NODAT, and an additional 16% had impaired fasting glucose. The incidence of NODAT in patients with HCV
was 26%. In multivariate analysis, HCV, pretransplant FPG, and LDLT were signiﬁcant. Each 10mg/dL increase in pretransplant
FPG was associated with a twofold increase in future development of NODAT. The incidence of NODAT after liver transplant in
patients oﬀ corticosteroids is 17%. Risk factors for developing NODAT include HCV and pretransplant FPG; LDLT is protective.
1.Introduction
Liver transplant recipients are at risk of a number of met-
abolic complications including new-onset diabetes mellitus,
hypertension, hyperlipidemia, and vascular disease. Many of
these complications are caused or exacerbated by immuno-
suppression. As graft survival has improved, transplant re-
cipients are increasingly aﬀected by the long-term complica-
tions of these metabolic conditions. Long-term management
of transplant recipients now highlights the importance of
identifying and managing the metabolic complications of
transplantation and immunosuppression [1].
New-onset diabetes after liver transplantation (NODAT)
is an incompletely understood phenomenon estimated to
occur in 15–30% of recipients who were not diabetic prior to
transplant[2].Diabetesmellitusiscommonintransplantre-
cipients and is associated with increased rates of rejection,
infection,cardiovasculardisease,andwithdecreasedsurvival
[2–6]. However, there is a wide variation in the reported
deﬁnition and incidence of NODAT due to heterogeneity of
study design, variability of corticosteroid dose and immuno-
suppression protocol, and deﬁnition of posttransplant dia-
betes mellitus. Additionally, many cirrhotic patients have di-
abetes prior to transplantation, and not all of the reported
literatureexcludedpatientswithpreexistingdiabetesmellitus
[2].
Diabetes mellitus exerts a signiﬁcant toll on the health of
liver transplant recipients. It is associated with an increased
rateofcardiovascularevents,infectiousdiseases,chronickid-
ney disease, rejection, and with lower patient survival [3, 5,
7]. These factors, in conjunction with the ﬁnancial burden of
managing diabetes mellitus, provide compelling reasons to
studythepreventionofNODAT.Identifyingpatientsathigh-
est risk of NODAT will help researchers design clinical pre-
vention trials.
The aims of this study were (1) to determine the inci-
dence of NODAT using the American Diabetes Association
(ADA) deﬁnition in a cohort of liver transplant recipients2 Journal of Transplantation
who were not diabetic prior to transplantation and who were
weaned oﬀ corticosteroids after transplantation and (2) to
determine pretransplant risk factors associated with NODAT
in this cohort.
2.MaterialsandMethods
2.1. Patients. This study was approved by the Mayo Clinic
Institutional Review Board. All nondiabetic patients under-
going initial liver transplantation at Mayo Clinic Arizona
were included. All patients had at least one year of followup.
FromJune1999throughFebruary2008,425livertransplants
were performed. Two hundred patients were excluded for
pretransplant diabetes mellitus (104), followup less than one
year (72), retransplantation (19), dual organ transplantation
(4), and other (1), leaving 225 patients in the study cohort.
Patients on corticosteroids before transplantation and after
the standard 4-month taper were excluded.
Pretransplant variables collected include age, gender,
race, etiology of liver disease, family history of diabetes mel-
litus, fasting plasma glucose (FPG), cholesterol, triglycerides,
body mass index, and model for end-stage liver disease
(MELD) score at the time of transplant. All MELD scores
were reported as the calculated value, and MELD exception
points were not included. The laboratory values were col-
lected from the most recent outpatient visit prior to trans-
plantation; the interval between laboratory collection and
transplantation was less than 3 months in all patients. Donor
variablescollectedincludeddonorage,gender,race,andhep-
atitis C status. Hepatitis C recipients who were not viremic
after transplantation, either due to spontaneous clearance or
antiviral therapy, were categorized into the non-HCV group
for analysis. At 1, 4, and 12 months after transplantation, the
following variables were recorded: body mass index, FPG,
immunosuppression, use of medication to control blood
sugar, and prednisone dose.
2.2. Immunosuppression. All patients followed a standard
immunosuppression protocol using tacrolimus and myco-
phenolate mofetil. All patients received 1gram of intra-
venous methylprednisolone on the day of transplant, follow-
ed by an oral course of prednisone which was tapered in a
standard fashion with cessation at 4 months after transplant.
In cases of neurotoxicity or other intolerance to tacrolimus,
cyclosporine was substituted. Mycophenolate mofetil was
adjusted or discontinued in cases of gastrointestinal side ef-
fects or myelosuppression. In rare cases of intolerance to cal-
cineurin inhibitors, rapamycin was substituted for tacrol-
imus or cyclosporine.
2.3. Deﬁnition of Diabetes Mellitus. NODAT was deﬁned us-
ing the ADA deﬁnition of diabetes [8]. NODAT was assessed
at one year after transplantation to exclude patients with
transient hyperglycemia related to the stress of surgery and
eﬀect of corticosteroids.
ADA deﬁnition of diabetes mellitus [8]:
(1) hemoglobin A1c ≥ 6.5%,
(2) fasting blood glucose ≥ 126mg/dL on 2 consecutive
occasions,
(3) random blood glucose ≥ 200mg/dL,
(4) blood glucose ≥ 200mg/dL 2 hours after drinking a
beverage containing 75 grams of glucose dissolved in
water after an overnight fast.
Impaired fasting glucose was deﬁned as a fasting plasma
glucose level of 100mg/dL to 125mg/dL.
2.4.StatisticalAnalysis. Continuousvariablesweredescribed
using mean, standard deviation, and t-tests. The chi-square
test was used for description of categorical variables. Logistic
regression was used to determine the risk associated with
pretransplant patient characteristics on the development of
NODAT. Unadjusted (univariate) logistic regression models
were initially performed followed by multivariate analysis of
variables that were statistically important in the univariate
analysis. A P value of < 0.05 was considered statistically
signiﬁcant.
3. Results
From June 1999 through February 2008, 225 nondiabetic pa-
tients underwent liver transplantation. Demographics of the
study patients are listed in Tables 1 and 2.
At one year after transplantation, the mean FPG was
106mg/dL, and 8% were using insulin (no patients were on
medications other than insulin for management of blood
sugar). Thirty-six percent of patients were obese, and 10%
were morbidly obese. At one year after transplant, 17% met
the ADA deﬁnition of diabetes mellitus, and 16% had im-
paired fasting glucose (Table 3). Of patients with HCV, the
incidence of NODAT was 26%.
Tacrolimus was the primary immunosuppressant in the
majority (91%) of patients after transplantation with myco-
phenolate as an adjunctive agent and a prednisone taper as
previously described. The NODAT+ and NODAT− groups
showed no diﬀerence in tacrolimus levels, episodes of acute
cellular rejection treated with intravenous steroids, or cu-
mulative steroid dose.
Univariate analysis results demonstrate that male gender,
presence of HCV, type of transplant (living-donor versus
deceased donor), and pretransplant FPG were signiﬁcantly
associated with NODAT (Table 4). In multivariate analysis,
HCV and pretransplant FPG were associated with NODAT,
whereas living-donor liver transplantation appeared to be
protective (Table 5). Each 10mg/dL increase in the fasting
plasmaglucosewasassociatedwith2-foldhigherrisk(OR2.1
CI 1.37–3.31) of development of NODAT (Figure 1). There
was no statistically signiﬁcant association observed between
patient age, ethnicity, family history of diabetes mellitus,
pre- or post-transplant body mass index, cholesterol, or
triglycerides and future NODAT.
4. Discussion
In this study, using the ADA deﬁnition of diabetes mellitus,
the incidence of NODAT one year after transplantation in
a steroid-free cohort of liver transplant recipients was 17%,
and an additional 16% had impaired fasting glucose.Journal of Transplantation 3
Table 1: Pretransplant demographics by development of NODAT.
NODAT− NODAT+ Total P value
N = 186 N = 39 N = 225
Recipient age, years 51.7 ± 10.4 51.2 ± 5.9 51.7 ± 9.8 0.76
Male gender, N (%) 127 (68.3) 33 (84.6) 160 (71.1) 0.04
Recipient race, N (%) 0.83
Caucasian 140 (75.2) 30 (76.9) 170 (76.6)
Hispanic 31 (16.7) 6 (15.4) 37 (16.4)
Other 12 (6.5) 2 (5.6) 14 (6.3)
Family history of DM, N (%) 58 (31.7) 16 (43.2) 74 (33.6) 0.17
Etiology of liver disease 0.001
HCV, N (%) 82 (44.1) 29 (74.3) 111 (49.3)
ALD, N (%) 29 (15.6) 2 (5.1) 31 (13.8)
Other 75 (40.3) 8 (20.5) 83 (36.9)
LDLT, N (%) 41 (22.0) 2 (5.1) 43 (19.1) 0.02
Calculated MELD 18.7 ± 8.5 18.5 ± 7.9 18.7 ± 8.4 0.88
BMI 27.8 ± 5.2 29.2 ± 5.1 28.1 ± 5.2 0.13
Obese (BMI ≥ 30) 71 (38.1) 17 (43.6) 88 (39.1) 0.4
Morbid obesity (BMI ≥ 40) 4 (2.1) 1 (2.6) 5 (2.2) 0.02
Pre-tx FPG (mg/dL) 91 ± 89 7 ± 10 92 ± 9 0.0001
Pre-tx IFG N (%) 16 (8.6) 8 (20.5) 24 (10.7) 0.03
Pre-tx cholesterol (mg/dL) 135 ± 107 113 ± 44 132 ± 99 0.21
Pre-tx triglycerides (mg/dL) 89 ± 51 92 ± 49 89 ± 51 0.74
Donor demographics
Male gender, N (%) 109 (58.6) 27 (69.2) 136 (60.4) 0.22
BMI, mean 26 ± 5.0 26.8 ± 5.7 26.1 ± 5.1 0.41
Age, years 40.1 ± 16.4 37.9 ± 16.3 39.7 ± 16.3 0.44
Hispanic race, N (%) 36 (19.3) 14 (35.9) 50 (22.2) 0.02
Continuous variables presented as means with standard deviations.
ALD: alcoholic liver disease, BMI:body mass index, DM: diabetes mellitus, FPG:fasting plasma glucose, HCV: hepatitis C virus, IFG:impaired fastinggl u c o s e ,
LDLT:living-donor liver transplantation, MELD:model for end-stage liver disease score.
Table 2: Pretransplant demographics of living-donor and deceased-donor recipients.
LDLT DDLT P value
N = 43 N = 182
Recipient age, years 49.1 ± 10.6 52.3 ± 9.5 0.06
Male gender, N (%) 26 (60.4) 134 (73.6) 0.09
Recipient race, N (%)
Caucasian 31 (72.1) 139 (76.4) 0.56
Hispanic 9 (20.9) 28 (15.4) 0.39
Family history of DM, N (%) 10 (23.3) 64 (35.2) 0.13
HCV, N (%) 19 (44.2) 92 (50.5) 0.56
Calculated MELD 14.2 ± 5.8 19.7 ± 8.6 0.0001
BMI 26.3 ± 4.6 28.5 ± 5.2 0.01
Pre-tx FPG (mg/dL) 90.2 ± 6.7 92.3 ± 9.2 0.15
Pre-tx cholesterol (mg/dL) 158.6 ± 68.5 125.2 ± 104.6 0.05
Pre-tx triglycerides (mg/dL) 85.4 ± 37.8 90.4 ± 53.6 0.57
LDLT:living-donor liver transplant.
DDLT:deceased-donor liver transplant.4 Journal of Transplantation
Table 3: Posttransplant variables by development of NODAT.
NODAT− NODAT+ Total P value
N = 186 N = 39 N = 225
One year
FPG (mg/dL) 98 ± 11.5 148 ± 50 106 ± 30 —
Hgb A1C 5.4 ± 0.3 6.3 ± 1.3 5.6 ± 0.7 —
BMI 27.1 ± 5.4 29.0 ± 6.9 27.5 ± 5.8 0.07
Tacrolimus level (ng/mL) 10.8 ± 3.2 11.3 ± 3.3 10.9 ± 3.2 0.4
Primary IS, N (%)
Tacrolimus 170 (91.4) 33 (84.6) 203 (90.2) 0.74
Cyclosporine 6 (3.2) 2 (5.1) 8 (3.6)
Sirolimus 10 (5.4) 3 (7.7) 13 (5.8)
Other 0 1 (2.6) 1 (0.4)
Steroid-treated rejection 0.2 ±.48 0.2 ±.47 0.2 ±.48 0.75
Cumulative steroid dose, mg 2811 ± 1447 2732 ± 1407 2797 ± 1437 0.75
NODAT 39 (17.3)
IFG, N (%) 36 (16)
Total abnormal glucose homeostasis, N (%) 75 (33.3)
Continuous variables presented as means with standard deviation.
BMI: body mass index, FPG:fasting plasma glucose, Hgb A1C:Hemoglobin A1C, IFG:impaired fasting glucose, IS:immunosuppression, NODAT:new-onset
diabetes after transplantation.
Table 4: Pretransplant predictors of NODAT in univariate analysis.
Predictor DM at 1 year 39/225 = 17%
OR (CI) P
Age per 1 year 0.99 (.9–1.0 ) 0.8
Male 2.6 (1.0–6.4) 0.05
Caucasian race 1.1 (.5–2.5) 0.8
Hispanic race 0.9 (.35–2.2) 0.8
Family history of DM 1.5 (.7–3.1) 0.2
HCV 3.7 (1.7–7.9) 0.001
BMI per 1 unit 1.05 (.9–1.1) 0.13
FPG per 10mg/dL 2.2 (1.4–3.4) 0.0001
Cholesterol per 1mg/dL 0.99 (.99–1.0) 0.16
Triglycerides per 1mg/dL 1.0 (.99–1.0 ) 0.7
LDLT 0.2 (.04–.83) 0.03
Age > 50 0.6 (.3–1.2) 0.13
FPG > 100mg/dL 4.6 (1.5–14.7) 0.009
Cholesterol > 200mg/dL 0.7 (.2–2.6) 0.6
Triglycerides > 200mg/dL 1.5 (.47–4.9) 0.5
BMI > 30 1.2 (.6–2.4) 0.7
Table 5: Pretransplant predictors of NODAT in multivariate
analysis.
Predictor OR (CI) P
FPG per 10mg/dL 2.1 (1.37–3.31) .001
LDLT .22 (0.05–0.98) .05
HCV 3.7 (1.64–8.36) .002
Abnormal glucose homeostasis thus occurred in 33% of
a cohort of liver transplant recipients on a standardized
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Figure 1: Incidence of NODAT by pretransplant fasting plasma
glucose (N = 225).
regimen of immunosuppression with tacrolimus, mycophe-
nolate mofetil, and a rapid steroid taper completing at 4
months. Independent predictors for NODAT include the
pretransplant fasting plasma glucose, the presence of hepati-
tis C virus, and the type of transplant (living-donor versus
deceased donor).
Inthegeneralpopulation,fastingplasmaglucosepredicts
the future development of type 2 diabetes mellitus, even
when the FPG is within the normal range [9]. Pretransplant
FPG has also been shown to predict NODAT in kidney trans-
plant recipients [10]. This eﬀect occurs not only in patients
with impaired fasting glucose, but also in those with FPG <
100mg/dL. In this way, NODAT appears to be similar to type
2 diabetes mellitus although additional research is needed to
determine if the pathophysiology is the same.
HepatitisCvirusisasubstantialandconsistentriskfactor
for the development of diabetes mellitus both before andJournal of Transplantation 5
afterlivertransplantation[11].Inlinewithcurrentliterature,
this study found hepatitis C virus to be a signiﬁcant risk
factor for development of NODAT, with an odds ratio
of 3.7 (CI 1.64–8.36). Prior studies have demonstrated a
correlation between insulin resistance and HCV viral load
[12], and fewer glucose abnormalities in sustained virologic
responders after antiviral therapy [13]. Another independent
risk factor was the pretransplant fasting plasma glucose, with
every 10mg/dL increase in the pretransplant fasting plasma
glucose resulting in a 2-fold increased risk of NODAT. This is
the ﬁrst report of a relationship between the pretransplant
FPG and the development of NODAT in a cohort of liver
transplant patients oﬀ corticosteroids.
Living-donor transplantation was noted as a protective
factor for the development of NODAT in one previous paper
[14], but the reasons remain unclear. In our study, the de-
ceased donor recipients had a higher calculated MELD score
than the living-donor recipients, indicating more advanced
disease in the deceased donor group. Glucose homeostasis is
a complex process requiring interplay between multiple hor-
mones and metabolic mediators and their eﬀects on liver,
skeletal,andadiposetissues.Chronicliverdisease,eveninthe
absence of HCV, is associated with altered glucose tolerance.
Glucose metabolism is signiﬁcantly impaired in patients
with chronic liver disease and worsens with more advanced
liver disease [15]. The higher incidence of NODAT noted in
deceased donor recipients may be a result of more inﬂam-
mation and more advanced liver disease as compared to the
living-donor recipients. Patient and graft survival of living-
donor liver transplant recipients has recently surpassed that
of deceased-donor liver transplant recipients [16]. Whether
a relationship exists between the development of NODAT
andoutcomesafterliving-donorlivertransplantationhasnot
been studied, and future research will address this question
further.
Another intriguing outcome of this study was the ﬁnding
that, in univariate analysis, donor Hispanic race was asso-
ciated with risk for NODAT. Hispanic race is a known risk
factor for type 2 diabetes mellitus in the general population
[17]. Race has been shown to be related to NODAT after
liver transplantation for African-American race but not for
Hispanic race [14]. The presence of diabetes in the donor is
also related to an increased risk of NODAT after liver trans-
plantation. Considering that Hispanic donors may be more
likelytohavediabetesthanCaucasiandonors,andthatdonor
diabetes increases the risk of NODAT, it is possible that
the increase in NODAT seen in recipients who received an
organ from a Hispanic donor may simply be due to a higher
prevalence of diabetes in this donor pool. The retrospective
design of this study is a limitation which precludes further
analysis of this observation.
The incidence of NODAT after liver transplantation ran-
ges from 18 to 36% in the literature [18, 19]. In this series,
17% of nondiabetic liver transplant recipients developed
NODAT at one year after transplantation. The range in in-
cidence is likely due to diﬀerences in study design and evo-
lution of immunosuppression management. For example,
older literature deﬁned NODAT with a fasting plasma glu-
cose > 140mg/dL [4] and did not exclude patients with
pretransplant diabetes [3] or those on corticosteroids [4, 19].
With the ADA criteria, we used a strict deﬁnition of NODAT
and delayed the diagnosis of diabetes until one year after
transplantationwhenallpatientshadbeenoﬀcorticosteroids
for 8 months.
Immunosuppression contributes to NODAT. Corticos-
teroids are known to be diabetogenic, likely due to the devel-
opment of insulin resistance. The use of corticosteroids has
been associated with NODAT, both when given as a bolus
administration for management of acute cellular re-
jection [3] and as the cumulative steroid dose [19]. Both tac-
rolimus and cyclosporine are known to be diabetogenic with
tacrolimus exerting a more substantial eﬀect [20]. In this
cohortonastandardizedandhomogenousimmunosuppres-
sion protocol, we could not evaluate the eﬀect of speciﬁc im-
munosuppressive agents on development of NODAT.
Thestrengthsofthisstudyincludealargesamplesize,the
use of a modern cohort of liver transplant recipients, use
of the ADA deﬁnition for diagnosis of NODAT, and a stan-
dardized immunosuppression protocol. Limitations include
the retrospective study design and the single-center cohort;
thus, these results may not be applicable to other transplant
groups.
In summary, abnormal glucose homeostasis occurs in
33% of liver transplant recipients who were not diabetic
prior to transplantation: NODAT develops in 17% and an
additional 16% of patients develop impaired fasting glucose
in the same time period. Pretransplant risk factors for the
development of NODAT include hepatitis C virus and
higher pretransplant fasting plasma glucose; living-donor
transplantation appears to be protective. Given the preva-
lence of abnormal glucose homeostasis in liver transplant
recipients, and its implication on long-term allograft and
patient survival, future study to risk stratify patients and
conduct preventive strategies is important.
List of Abberviations
NODAT: New-onset diabetes after transplant
ADA: American Diabetes Association
FPG: Fasting plasma glucose
MELD: Model for end-stage liver disease score
HCV: Hepatitis C virus.
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